General MedicationsSubcutaneousStandard
ALHEMO
CONCIZUMAB-MTCI
Standard Dose
300MG/3ML(100MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview ALHEMO is listed in Drugs@FDA under application 761315 (BLA).
Review priority: STANDARD Marketing status: Prescription Active ingredient CONCIZUMAB-MTCI Form and strength Injectable; Subcutaneous - 300MG/3ML(100MG/ML) Sponsor NOVO NORDISK INC Submission history Latest submission status date: 2025-07-31 00:00:00.
Structured Monograph
Clinical summary
Approval overview ALHEMO is listed in Drugs@FDA under application 761315 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient CONCIZUMAB-MTCI Form and strength Injectable; Subcutaneous - 300MG/3ML(100MG/ML) Sponsor NOVO NORDISK INC Submission history Latest submission status date: 2025-07-31 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.